Analgesic Use and Patterns of Estrogen Metabolism in Premenopausal Women

Hormones and Cancer

Volumn 5, Issue 2, 2014, Pages 104-112

  Fortner, Renée T ^a,b   Oh, Hannah ^a,b   Daugherty, Sarah E ^c   Xu, Xia ^d   Hankinson, Susan E ^a,b,e   Ziegler, Regina G ^c   Eliassen, A Heather ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 HYDROXYESTRONE 3 METHYL ETHER; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; CATECHOL DERIVATIVE; CREATININE; EPIMESTROL; ESTRADIOL; ESTROGEN; ESTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; ESTROGEN METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MENSTRUAL CYCLE; METABOLISM; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; URINALYSIS; DRUG UTILIZATION; MIDDLE AGED; NURSE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TANDEM MASS SPECTROMETRY; URINE;

ACETAMINOPHEN; ADULT; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; ESTROGENS; FEMALE; HUMANS; LINEAR MODELS; LUTEAL PHASE; MIDDLE AGED; NURSES; PREMENOPAUSE; QUESTIONNAIRES; TANDEM MASS SPECTROMETRY;

EID: 84897985121     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0167-5     Document Type: Article

References (28)

1. Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17: 871-888. doi: 10. 1007/s10552-006-0033-7.
2. Bosetti C, Rosato V, Gallus S et al (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23: 1403-1415. doi: 10. 1093/annonc/mds113.
3. González-Pérez A, García Rodríguez LA, López-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3: 28. doi: 10. 1186/1471-2407-3-28.
4. Dubé C, Rostom A, Lewin G et al (2007) The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 146: 365-375.
5. Rostom A, Dubé C, Lewin G et al (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 146: 376-389.
6. Luo T, Yan H-M, He P et al (2012) Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 131: 581-587. doi: 10. 1007/s10549-011-1747-0.
7. Takkouche B, Regueira-Méndez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100: 1439-1447. doi: 10. 1093/jnci/djn324.
8. Eliassen AH, Chen WY, Spiegelman D et al (2009) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 169: 115-121. discussion 121 doi: 10. 1001/archinternmed. 2008. 537.
9. Zhang X, Smith-Warner SA, Collins LC et al (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. JCO 30: 3468-3477. doi: 10. 1200/JCO. 2012. 42. 2006.
10. Gunter MJ, Hoover DR, Yu H et al (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68: 329-337. doi: 10. 1158/0008-5472. CAN-07-2946.
11. Clendenen TV, Koenig KL, Shore RE et al (2009) Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18: 275-281. doi: 10. 1158/1055-9965. EPI-08-0777.
12. Key T, Appleby P, Barnes I et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94: 606-616.
13. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE (2013) Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137: 883-892. doi: 10. 1007/s10549-012-2391-z.
14. Bauer SR, Fortner RT, Gates MA et al (2013) Analgesic use in relation to sex hormone and prolactin concentrations in premenopausal women. Cancer Causes Control 24: 1087-1097. doi: 10. 1007/s10552-013-0186-0.
15. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282. doi: 10. 1056/NEJMra050776.
16. Seeger H, Wallwiener D, Kraemer E, Mueck AO (2006) Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54: 72-77. doi: 10. 1016/j. maturitas. 2005. 08. 010.
17. Xu X, Veenstra TD, Fox SD et al (2005) Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 77: 6646-6654. doi: 10. 1021/ac050697c.
18. Falk RT, Xu X, Keefer L et al (2008) A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 17: 3411-3418. doi: 10. 1158/1055-9965. EPI-08-0355.
19. Eliassen AH, Spiegelman D, Xu X et al (2012) Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 72: 696-706. doi: 10. 1158/0008-5472. CAN-11-2507.
20. Fortner RT, Eliassen AH, Spiegelman D et al (2013) Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II. Breast Cancer Res 15: R19. doi: 10. 1186/bcr3394.
21. Eliassen AH, Ziegler RG, Rosner B et al (2009) Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 18: 2860-2868. doi: 10. 1158/1055-9965. EPI-09-0591.
22. Ziegler RG, Faupel-Badger JM, Sue LY et al (2010) A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 121: 538-545. doi: 10. 1016/j. jsbmb. 2010. 03. 068.
23. Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 165-172.
24. Brueggemeier RW, Su B, Sugimoto Y et al (2007) Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol 106: 16-23. doi: 10. 1016/j. jsbmb. 2007. 05. 021.
25. Brueggemeier RW, Díaz-Cruz ES, Li P-K et al (2005) Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 95: 129-136. doi: 10. 1016/j. jsbmb. 2005. 04. 013.
26. Hinz B, Cheremina O, Brune K (2008) Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22: 383-390. doi: 10. 1096/fj. 07-8506com.
27. Straus JF III (2004) The synthesis and metabolism of steroid hormones. In: Straus JF III, Barbieri RL (eds) Yen and Jaffe's reproductive endocrinology, 5th edn. Elsevier Saunders, Philadelphia, pp 125-154.
28. Miller WR, Larionov AA (2012) Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 14: 201. doi: 10. 1186/bcr2931.